Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)

Overview of Performance

In the third quarter of the fiscal year ending March 2026, net sales were 28,719 million yen (4.3% decrease year-over-year), operating income was 2,088 million yen (38.7% decrease year-over-year), and quarterly net income attributable to owners of the parent was 1,438 million yen (47.4% decrease year-over-year). Pressure on cost reductions at medical institutions and intensified competition with rival products significantly impacted operating and net income. Selling, general and administrative expenses increased due to higher investment-related costs including recruitment, research and development, and digital transformation (DX) expenses. The equity ratio improved to 78.8% compared to the same period last year.

Outlook and Management Policy

The full-year consolidated earnings forecast anticipates net sales of 39,240 million yen (0.3% increase compared to previous fiscal year), operating income of 2,770 million yen (27.3% decrease), and net income attributable to owners of the parent of 2,030 million yen (33.5% increase). We will strengthen value-added proposals focusing on key facilities, emphasize promotion of premium kits and acquisition of new customers. Although manufacturing costs are expected to increase due to rising raw material prices, efforts will be made to reduce costs and improve productivity. We will promote structural reforms based on the medium-term management plan aiming for sustainable mid- to long-term growth.